| Autor: |
K. Ellan, M.R.Mohd Abd. Razak, A. Muhammad, N.H. Jelas, M. Farhan, E. Tiagaraj, S.K. Yee, V. Jicob, Z. Zawawi, M.Z. Wahid, M.A. Azizan, J. Kalyanasundram, A. Adiee, A. Zulkapli, W.M.A.A. Zainuzzaman, N. Bahrin, M. Mayasari, J. Lee, P. Patrick, C. Keong, R. Mohd Zain, A.F. Mohamed, V. Sabaratnam, R. Thayan, K. Kamel |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
International Journal of Infectious Diseases, Vol 130, Iss , Pp S62- (2023) |
| Druh dokumentu: |
article |
| ISSN: |
1201-9712 |
| DOI: |
10.1016/j.ijid.2023.04.156 |
| Popis: |
Intro: An effective antiviral therapies are currently unavailable for the treatment of DENV infection. Schizophyllum commune aqueous extract (ScASE) had been reported for the anti-dengue effect in in-vitro studies using plaque reduction assay and real time RT-PCR. This study explored the ability of this mushroom extract to give in vivo protection against dengue virus infection in the AG129 mouse model. Methods: Male AG129 mice at the age of 8 weeks were assigned into five groups of six: mock infected, DENV 2 infected, DENV 2 infected treated orally with ScASE (500 mg/kg), DENV 2 infected treated intraperitoneally with ScASE (500 mg/kg) and DENV2 infected treated intraperitoneally with celgosivir (15 mg/kg). The treatment doses were administered twice daily for 4 days. During the experiment, mice were weighed daily and their disease progression was visually monitored. At day 1, day 3, and day 5 post-infection, blood samples were collected for assessment of DENV titer by real time RT-PCR, NS1 Ag and inflammatory cytokine levels. Findings: After receiving intraperitoneal injections of 500 mg/kg of ScASE twice daily for four days, infected AG129 mice totally recovered from the disease and regained weight seven days after infection. The level of NS1 Ag significantly decreased to 80.12% while the quantity of viral RNA significantly reduced to 67.84%. On day 5 post-infection, strong anti-inflammatory effects were observed against the production of inflammatory cytokines, with percentage reductions of 45.8% for IL-6, 37.6% for IL-10, 78.3% for IL-12, 48.4% for MCP1, and 52.2% for TNF-α. Conclusion: This is a preliminary study that shown the potential of ScASE as an anti-dengue therapeutic drug in the AG129 mouse model. Before entering phase 1 clinical trial with human subjects, additional research must be carried out. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
